ArticleInternational forum of allergy & rhinology2026
Female-Specific Risk of TAS2R Variants in Chronic Rhinosinusitis: A Hospital-Based Cohort Study From the Taiwan Precision Medicine Initiative.
Article in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetic Variants Influencing Taste Perception and Food Preferences: Current Evidence.Nutrients · 2026Review
- Comment on "Female-Specific Risk of TAS2R Variants in Chronic Rhinosinusitis: A Hospital-Based Cohort Study From the Taiwan Precision Medicine Initiative".International forum of allergy & rhinology · 2026Article
- Reply to: Comment on "Female-Specific Risk of TAS2R Variants in Chronic Rhinosinusitis: A Hospital-Based Cohort Study From the Taiwan Precision Medicine Initiative".International forum of allergy & rhinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBitter taste receptors (T2Rs) function in the innate immune defense of the sinonasal mucosa; however, the genetic association between the TAS2R gene family and chronic rhinosinusitis (CRS) remains understudied in Asian populations. This study aimed to investigate the impact of these genetic variants on CRS susceptibility using a large East Asian Han Chinese genomic database.
methodsThis retrospective case‒control study analyzed the Taiwan Precision Medicine Initiative dataset. We included 826 patients with CRS and 8260 control subjects. Controls were screened using ICD codes to exclude other upper airway disorders and were matched 1:10 to cases by age and sex. Univariable and multivariable logistic regression models, adjusted for relevant clinical covariates, were used to evaluate the independent effects of TAS2R genetic variants. We also conducted stratified analyses based on biological sex and clinical CRS phenotypes.
resultsMultivariable analysis identified TAS2R38 (rs77730028: adjusted odds ratio [aOR] = 1.363, p < 0.001) and TAS2R42 (rs1669424: aOR = 1.143, p = 0.039) as independent risk factors for CRS, whereas TAS2R1 (rs385: aOR = 0.912, p = 0.019) demonstrated a significant protective effect. Our study revealed a marked sexual dimorphism: these genetic associations were almost exclusively driven by the female cohort (in females, the risk effect of TAS2R38 reached an aOR of 1.709, p < 0.001, with no significant association observed in males). The risk effect of TAS2R38 remained consistent across both patients with CRS with nasal polyps and those without nasal polyps.
conclusionGenetic variations within the TAS2R family significantly influence the risk of developing CRS in the Han Chinese population, demonstrating a specific female-driven effect. These findings help classify CRS endotypes and suggest that biological sex should be considered in future precision medicine and targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.